91 related articles for article (PubMed ID: 9951454)
1. [Raloxifene].
Hofbauer LC; Heufelder AE
Dtsch Med Wochenschr; 1999 Jan; 124(1-2):19-20. PubMed ID: 9951454
[No Abstract] [Full Text] [Related]
2. Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.
Park L; Evans MF
Can Fam Physician; 1999 May; 45():1191-3. PubMed ID: 10349062
[No Abstract] [Full Text] [Related]
3. Raloxifene: a new class of anti-estrogens for the prevention of osteoporosis.
Kupecz D
Nurse Pract; 1998 Sep; 23(9):91-3. PubMed ID: 9778672
[No Abstract] [Full Text] [Related]
4. [Current trends in prevention and therapy of postmenopausal osteoporosis].
Rossi G
Recenti Prog Med; 1998 Jun; 89(6):288. PubMed ID: 9658894
[No Abstract] [Full Text] [Related]
5. Raloxifene: a selective estrogen receptor modulator.
Scott JA; Da Camara CC; Early JE
Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen for prevention of breast cancer.
Med Lett Drugs Ther; 1999 Jan; 41(1043):1-2. PubMed ID: 9924486
[No Abstract] [Full Text] [Related]
7. Raloxifene for postmenopausal osteoporosis.
Med Lett Drugs Ther; 1998 Mar; 40(1022):29-30. PubMed ID: 9529516
[No Abstract] [Full Text] [Related]
8. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
[TBL] [Abstract][Full Text] [Related]
9. A new alternative to estrogen: raloxifene.
Runowicz C
Health News; 1998 Jun; 4(8):4. PubMed ID: 9644506
[No Abstract] [Full Text] [Related]
10. Clinical efficacy of SERMs.
Dere WH
Aging (Milano); 1998 Apr; 10(2):160-1. PubMed ID: 9666217
[No Abstract] [Full Text] [Related]
11. From blunderbuss to magic bullet?
Alderman C
Nurs Stand; 1998 Jan 21-27; 12(18):18. PubMed ID: 9485842
[No Abstract] [Full Text] [Related]
12. Effects of raloxifene in postmenopausal women.
Friedman MN
N Engl J Med; 1998 Apr; 338(18):1313; author reply 1313-4. PubMed ID: 9565493
[No Abstract] [Full Text] [Related]
13. Designer estrogens: breast cancer benefit, remaining questions.
Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
[No Abstract] [Full Text] [Related]
14. Raloxifene reduces spinal fractures postmenopausally.
MacReady N
Lancet; 1999 Aug; 354(9179):653. PubMed ID: 10466676
[No Abstract] [Full Text] [Related]
15. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
Lufkin EG; Whitaker MD; Nickelsen T; Argueta R; Caplan RH; Knickerbocker RK; Riggs BL
J Bone Miner Res; 1998 Nov; 13(11):1747-54. PubMed ID: 9797484
[TBL] [Abstract][Full Text] [Related]
16. I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a day to stave off osteoporosis. What's left?
Robb-Nicholson C
Harv Womens Health Watch; 1998 Nov; 6(3):8. PubMed ID: 9814138
[No Abstract] [Full Text] [Related]
17. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Jordan VC
J Natl Cancer Inst; 1998 Jul; 90(13):967-71. PubMed ID: 9665143
[No Abstract] [Full Text] [Related]
18. Using SERMS for treating postmenopausal symptoms.
Brockie J
Community Nurse; 1999 Jan; 4(12):30-1. PubMed ID: 10326399
[No Abstract] [Full Text] [Related]
19. New drug approved to help prevent osteoporosis.
Mayo Clin Health Lett; 1998 Mar; 16(3):3. PubMed ID: 9516369
[No Abstract] [Full Text] [Related]
20. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.
Nickelsen T; Lufkin EG; Riggs BL; Cox DA; Crook TH
Psychoneuroendocrinology; 1999 Jan; 24(1):115-28. PubMed ID: 10098223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
